Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arrowhead Pharma (NQ: ARWR )

25.40 +0.97 (+3.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,184,459
Open 24.59
Bid (Size) 25.40 (99)
Ask (Size) 25.49 (1)
Prev. Close 24.43
Today's Range 24.43 - 25.56
52wk Range 23.09 - 51.11
Shares Outstanding 105,736,200
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Want Diversified Upside in Biotechnology? Check out LABU
Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility. 
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities

Performance

YTD
-34.04%
-34.04%
1 Month
-21.68%
-21.68%
3 Month
-34.04%
-34.04%
6 Month
-24.72%
-24.72%
1 Year
-48.37%
-48.37%

More News

Read More
Analyst Ratings for Arrowhead Pharma
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
Arrowhead Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Earnings Outlook For Arrowhead Pharmaceuticals
Via Benzinga
Arrowhead Receives FDA Fast Track Designation for ARO-APOC3
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals
Via Benzinga
Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Why Omeros Are Trading Higher By 32%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Energizer, Children's Place And Other Big Stocks Moving Lower On Monday
Via Benzinga
Earnings Scheduled For February 6, 2023
Via Benzinga
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
Via Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Arrowhead Pharmaceuticals Stock Is Diving Today
Via Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Via Investor's Business Daily
Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.